Journal
JOURNAL OF NEUROLOGY
Volume 269, Issue 3, Pages 1114-1120Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-021-10803-3
Keywords
COVID-19; SARS-COV-2; Multiple sclerosis
Categories
Funding
- Italian MS Society (Associazione Italiana Sclerosi Multipla)
- Genzyme
- Biogen
- Sanofi-Aventis
- Merck Serono
- Bayer-Schering
- Teva
- Almirall
- Roche
- Novartis
- CSL Behring
Ask authors/readers for more resources
The pooled analysis indicates a 24% increased risk of death from COVID-19 in patients with multiple sclerosis. However, confirmation in larger population-based studies is needed due to difficulties in COVID-19 case detection and cohort heterogeneity.
Objective To estimate whether the risk of death from COVID-19 in patients with multiple sclerosis (MS) exceeds that of the general population. Methods We conducted a pooled analysis of cohort studies on COVID-19 in patients with MS published until July 31, 2021. We calculated the pooled crude death rate (CDR) and estimated the indirectly-adjusted age-standardized lethality ratio (SLR) to assess the risk of death from COVID-19 in patients with MS as compared to general population. Results Out of 520 articles, 18 fulfilled criteria for pooled analysis, with a total of 5634 patients (28.6% males, mean age 41.8 years). Of them, 111 died, yielding a CDR of 1.97% (95% confidence intervals [CIs] 1.61-2.33). The estimated SLR was 1.24 (95% CIs 1.01-1.48) after indirect age-standardization using case-fatality rates obtained from the detailed surveillance data available at the World Health Organization (WHO) website. A leave-one-out sensitivity analysis and the analysis of temporal trends of SLR from March 2020 to July 2021 provided consistent findings. Conclusions Our pooled analysis suggests a 24%-increased risk of death from COVID-19 in patients with MS. These findings must be interpreted with caution, mainly because of the difficulties in COVID-19 case detection (especially in the first pandemic wave) and heterogeneity of the analyzed cohorts. Confirmation in larger population-based studies is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available